Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin
NVIDIA Brian Caulfield
Bristol Myers Squibb deployed its second NVIDIA DGX SuperPOD with eight Vera Rubin NVL72 systems, doubling down on AI infrastructure for drug discovery. The new system delivers 10x the performance per megawatt compared to its predecessor and will be accessible to all BMS scientists globally through a unified AI platform including NVIDIA BioNeMo Agent Toolkit. This removes computational bottlenecks and enables faster drug discovery cycles by democratizing access to supercomputing resources across the organization's research pipeline.
Why it matters
Erin Davis calls it the “SuperDuperPOD.” That’s two things in one name: pharmaceutical giant Bristol Myers Squibb (BMS) already runs one of the largest AI clusters in life sciences, with serious results to show for it. And they’re doubling down. BMS announced today it is deploying its second NVIDIA DGX SuperPOD, this one built on […]
